The future of scientific discovery is increasingly linked to the development of AI-ready laboratories, as highlighted by recent reports. Behind every new cancer drug, diagnostic test, or vaccine is a laboratory conducting extensive research, often involving thousands of experiments refined over time. Traditionally, this work has been done manually, with scientists spending significant time on repetitive tasks such as preparing and moving samples. These processes require precision and take time away from interpreting findings and deciding on next steps. This is beginning to change, with companies like London-based Automata Technologies leading the shift. Automata develops lab automation infrastructure for life sciences labs, combining robotics and software with existing scientific instruments. This connected infrastructure is becoming crucial as life sciences organizations prepare for the wider use of AI in the lab. Coordinating instruments, workflows, and data can increase throughput and create more walkaway time, allowing experiments to run more consistently and, in some cases, without constant supervision. This enables labs to test more ideas and identify promising results sooner without increasing headcount or facilities, potentially shortening the path to new medicines and expanding access to diagnostic testing. For many life sciences organizations, the challenge is no longer whether to automate their labs but how to do it effectively. Pharmaceutical, biotechnology, and diagnostics organizations are under pressure to move faster, produce more reliable data, and achieve more with existing people and resources. AI has raised the stakes further by enabling data analysis and helping researchers identify what to test next. However, realizing the full value of AI depends on labs being able to carry out those experiments and return reliable, usable results. Much of today’s lab automation is not equipped to support this. Equipment can automate individual stages but may not communicate with what comes before or after, leaving scientists to move samples and information between them. Vendor lock-in can exacerbate this problem by tying labs to closed systems that are difficult to adapt as scientific and AI requirements evolve. Automata Technologies has built its approach around closing these gaps. Rather than adding another isolated tool, Automata starts from the observation that automation creates the most value when it works as a connected system, not as a collection of automated steps. This thinking shapes Automata’s work across commercial and academic life sciences, serving scientists running experiments, as well as the R&D and operations leaders responsible for how the wider lab performs and scales. Automata’s approach is built on three principles: full integration, ease of use, and AI readiness. Full integration requires instruments, workflows, and data to connect end-to-end, regardless of vendor, allowing labs to adapt their equipment and processes over time without being tied to a single manufacturer’s ecosystem. Ease of use ensures that scientists and automation engineers can work within the same system without unnecessary friction, balancing depth for specialists with accessibility for others involved in the workflow. AI readiness involves building structured data and flexible architecture that allow AI models to be applied meaningfully to lab operations. These principles are embodied in Automata’s LINQ platform, which combines modular lab hardware, orchestration software that coordinates instruments and workflows, and an open data architecture into a single system. The goal is not automation for its own sake but a shift toward lab operations that are more reliable, scalable, and increasingly autonomous over time. As AI reshapes the life sciences sector, Automata emphasizes that the real differentiator is whether the lab can operate as a connected whole: integrated, usable, and ready for future applications of AI.